Tools

LEADER 03494cam a22004454a 4500

005 20141212015510.0;

008 010327s2001 nyua b 101 0 eng c;

010 a| 2001021760;

016 7 a| 1010915532| DNLM;

019 a| 46599979;

020 a| 1842140388 (alk. paper) :c| $63.96;

035 a| (Sirsi) H1018253;

035 a| (OCoLC)46634766;

042 a| pcc;

049 a| NEHH;

245 00 a| Hormone replacement therapy and cardiovascular disease /c| edited by A.R. Genazzani.;

300 a| viii, 188 pages :b| illustrations ;c| 26 cm.;

336 a| text2| rdacontent;

337 a| unmediated2| rdamedia;

338 a| volume2| rdacarrier;

490 1 a| Controversial issues in climacteric medicine series;

504 a| Includes bibliographical references and index.;

505 0 a| Ch. 1. Trends in mortality rates for cardiovascular and cerebrovascular diseases in developed countries -- Ch. 2. Cardiovascular aging in women and men in the absence of clinical disease -- Ch. 3. Lipid metabolism -- Ch. 4. Diabetes, obesity and cardiovascular disease -- Ch. 5. Endothelial function in hypertension: role of gender -- Ch. 6. Venous thromboembolism and hormone replacement therapy -- Ch. 7. Acute coronary syndromes in women -- Ch. 8. Estrogen receptor-β and women's health -- Ch. 9. Molecular biology of selective estrogen receptor modulators -- Ch. 10. The estrogen receptor knock-out mouse model -- Ch. 11. Sex steroids in the cardiovascular system: molecular mechanisms of action -- Ch. 12. Progestins and the cardiovascular system -- Ch. 13. Sex steroids and the cardiovascular system in vivo: actions in animal models -- Ch. 14. Sex steroids and the cardiovascular system in vivo: actions in humans -- Ch. 15. Sex steroids and blood coagulation -- Ch. 16. Lipoprotein-associated estrogen: the role of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein -- Ch. 17. Cardiovascular effects of hormone replacement therapy: what factors may influence risk? -- Ch. 18. Effects of transdermal hormone replacement therapy on cardiovascular outcomes: epidemiological evidence -- Ch. 19. Pulsed estrogen therapy: Aerodiol® -- Ch. 20. Cardiovascular effects of raloxifene: data from preclinical studies and clinical trials in postmenopausal women -- Ch. 21. Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial®) -- Ch. 22. Hormone replacement therapy and myocardial infarction -- Ch. 23. Hormonal replacement therapy, venous thromboembolism and stroke.;

650 12 a| Cardiovascular Diseasesx| drug therapyv| Congresses.=| ^A919517;

650 12 a| Cardiovascular Diseasesx| prevention & controlv| Congresses.=| ^A919799;

650 22 a| Cardiovascular Systemx| drug effectsv| Congresses.=| ^A919518;

650 22 a| Hormone Replacement Therapyx| methodsv| Congresses.=| ^A943732;

650 22 a| Postmenopausex| drug effectsv| Congresses.=| ^A1204701;

650 22 a| Women's Healthv| Congresses.=| ^A919344;

700 1 a| Genazzani, Andrea R.=| ^A541907;

830 0 a| Controversial issues in climacteric medicine series.=| ^A935689;

994 a| E0b| NEH;

919 a| BOOK;

959 a| 1018253;

096 a| WG 166 C764 2001;

596 a| 4;

998 a| 1559465;

999 a| WG 166 C764 2001w| NLMc| 1i| 31740007239472d| 2/23/2011e| 6/18/2008f| 2/23/2011g| 2l| HSLBKm| HSLn| 2p| $63.96r| Ys| Yt| HBKu| 11/16/2001x| BOOKz| HSTACKSo| .STAFF. 0;

Hormone replacement therapy and cardiovascular disease / edited by A.R. Genazzani.

Other author	Genazzani, Andrea R.
Format	Book
Publication Info	New York : Parthenon Pub. Group, ©2001.
Description	viii, 188 pages : illustrations ; 26 cm.
Subjects	Cardiovascular Diseases--drug therapy. --Congresses. Cardiovascular Diseases--prevention & control. --Congresses. Cardiovascular System--drug effects. --Congresses. Hormone Replacement Therapy--methods. --Congresses. Postmenopause--drug effects. --Congresses. Women's Health--Congresses.

Series	Controversial issues in climacteric medicine series Controversial issues in climacteric medicine series. ^A935689
Contents	Ch. 1. Trends in mortality rates for cardiovascular and cerebrovascular diseases in developed countries -- Ch. 2. Cardiovascular aging in women and men in the absence of clinical disease -- Ch. 3. Lipid metabolism -- Ch. 4. Diabetes, obesity and cardiovascular disease -- Ch. 5. Endothelial function in hypertension: role of gender -- Ch. 6. Venous thromboembolism and hormone replacement therapy -- Ch. 7. Acute coronary syndromes in women -- Ch. 8. Estrogen receptor-β and women's health -- Ch. 9. Molecular biology of selective estrogen receptor modulators -- Ch. 10. The estrogen receptor knock-out mouse model -- Ch. 11. Sex steroids in the cardiovascular system: molecular mechanisms of action -- Ch. 12. Progestins and the cardiovascular system -- Ch. 13. Sex steroids and the cardiovascular system in vivo: actions in animal models -- Ch. 14. Sex steroids and the cardiovascular system in vivo: actions in humans -- Ch. 15. Sex steroids and blood coagulation -- Ch. 16. Lipoprotein-associated estrogen: the role of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein -- Ch. 17. Cardiovascular effects of hormone replacement therapy: what factors may influence risk? -- Ch. 18. Effects of transdermal hormone replacement therapy on cardiovascular outcomes: epidemiological evidence -- Ch. 19. Pulsed estrogen therapy: Aerodiol® -- Ch. 20. Cardiovascular effects of raloxifene: data from preclinical studies and clinical trials in postmenopausal women -- Ch. 21. Cardiovascular risk assessment for postmenopausal hormone replacement therapies such as tibolone (Livial®) -- Ch. 22. Hormone replacement therapy and myocardial infarction -- Ch. 23. Hormonal replacement therapy, venous thromboembolism and stroke.
Bibliography note	Includes bibliographical references and index.
LCCN	2001021760
ISBN	1842140388 (alk. paper) :

Availability

Library	Location	Call Number	Status	Item Actions
Laupus	Books - Stacks	WG 166 C764 2001	✔ Available	Place Hold

Hormone replacement therapy and cardiovascular disease / edited by A.R. Genazzani.

Click here for more information about this title

Availability